Understanding how certain cancer cells respond to new therapies in pancreatic cancer
Exploring the molecular mechanisms controlling CDK7i sensitivity in pancreas cancer
This study is looking at why some pancreatic cancer cells respond better to a specific treatment and how a protein called SIRT6 affects this response, with the goal of finding better treatment options for patients with a tough type of pancreatic cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10997000 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that make some pancreatic cancer cells more sensitive to a specific type of therapy targeting CDK7. The study focuses on a subtype of pancreatic cancer known as basal pancreatic ductal adenocarcinoma, which has a poorer prognosis. Researchers will explore how a protein called SIRT6 influences the stability of another protein, ATF4, and how this interaction affects the cancer cells' response to treatment. By using mouse models that closely mimic human pancreatic cancer, the research aims to identify effective treatment strategies for patients with this aggressive cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with basal pancreatic ductal adenocarcinoma who are seeking new treatment options.
Not a fit: Patients with other types of pancreatic cancer or those who are not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer, particularly those with the basal subtype.
How similar studies have performed: Previous research has shown promising results in targeting similar molecular pathways in other cancers, suggesting potential for success in this approach.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Wallace-Povirk, Adrianne — Fred Hutchinson Cancer Center
- Study coordinator: Wallace-Povirk, Adrianne
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.